Abstract:Lysine-specific demethylase 1 (LSD1) is frequently elevated in acute myeloid leukemia (AML) and often leads to tumorigenesis. In recent years, numerous LSD1 inhibitors based on tranylcypromine (TCP) scaffolding have reached clinical trials. Most TCP derivatives were modified at the amino site of cyclopropane motif. Herein, we for the first time introduced a sulfonamide group in TCP benzene ring of series a compounds and performed a systematical study on structure and activity relationships by varying sulfonamide groups. The introduction of sulfonamide significantly increased the targeting capacity of TCP against LSD1. Moreover, we discovered that the Boc attached LSD1 inhibitors (labelled as series b compounds) substantially improved their anti-proliferation capacity towards AML cells. The intracellular thermal shift and LC-MS/MS results implied that Boc enhanced the drug lipophilicity and might be removed under the cancerous acidic environment to release the real pharmacophore, evidenced by the fact that a structurally similar but acidic inert pivaloyl to replace Boc dramatically dropped the cellular anti-proliferation effect. Finally, a benzyl group installed at the amino site to appropriately increase lipophilicity led to trans-4-(2-(benzylamino)-cyclopropyl)-N,N-diethylbenzenesulfonamide a10 that showed better anti-proliferation activity in AML cells and enzymatic inhibition against LSD1. Taken together, our work offers a novel TCP-based structure and provides a prodrug strategy for the discovery of potent LSD1 inhibitors by having appropriate lipophilicity.

Structure–Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors

Optimization and Biological Evaluation of Novel 1H-Pyrrolo[2,3-c]pyridin Derivatives As Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia

Synthesis and biological evaluation of novel (E)-N’-(2, 3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors

Discovery of Natural Product-Like Spirooxindole Derivatives As Highly Potent and Selective LSD1/KDM1A Inhibitors for AML Treatment.

Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors

Design, Synthesis, and Structure-Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine-Thiourea Hybrids As Potent, Orally Active Antitumor Agents.

Design, Synthesis and Biological Activity of 3-Oxoamino-benzenesulfonamides As Selective and Reversible LSD1 Inhibitors.

Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation

Design, Synthesis and Biological Activity of 4-(4-benzyloxy)phenoxypiperidines As Selective and Reversible LSD1 Inhibitors.

Design, synthesis and biological evaluation of 2-aminopyrimidine-based LSD1 inhibitors

Development of the Triazole-Fused Pyrimidine Derivatives As Highly Potent and Reversible Inhibitors of Histone Lysine Specific Demethylase 1 (LSD1/KDM1A)

Optimization and Biological Evaluation of Novel 1 H -Pyrrolo[2,3- c ]pyridin Derivatives as Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia

Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)

Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment

Synthesis, optimization and antitumor activity evaluation of sulfonyl benzoyl hydrazide derivatives as novel human LSD1 inhibitors

Identification of Novel Selective Lysine‐Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore‐Based Virtual Screening Combined with Docking

New Tranylcypromine Derivatives Containing Sulfonamide Motif As Potent LSD1 Inhibitors to Target Acute Myeloid Leukemia: Design, Synthesis and Biological Evaluation

Design Two Novel Tetrahydroquinoline Derivatives Against Anticancer Target LSD1 with 3D-QSAR Model and Molecular Simulation

Molecular docking, 3D-QSAR, and molecular dynamics simulations of thieno[3,2-b]pyrrole derivatives against anticancer targets of KDM1A/LSD1

Optimization of 5-Arylidene Barbiturates As Potent, Selective, Reversible LSD1 Inhibitors for the Treatment of Acute Promyelocytic Leukemia.